What You Should Know:
- The U.S. digital therapeutics market size is estimated to reach $21.46B by 2030, expanding at a CAGR of 33.8% from 2023 to 2030, according to a new reports by Coherent Market Insights, Inc.
- Digital therapeutics solutions help improve medication adherence with personalized incentives to encourage long-term behavior change in patients and people with chronic conditions. The report reveals government initiatives to digitalize healthcare is one of the key trends expected to boost the growth of the U.S. digital therapeutics market over the next few years.
Understanding Digital Therapeutics
Digital therapeutics (DTx) are evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or a disease. Digital therapeutics are on-demand and personalized, helping patients manage their conditions as well as giving them the opportunity to seek support in their moment of need. DTx technologies and/or services have been developed with the aim of increasing the patient’s accessibility to effective and clinically safe treatments, extending physician’s ability to treat patients, providing clinical solutions for untreated or undertreated health conditions, and providing accurate results and information on personalized disease management and outcomes to patients and physicians.
Key findings of the report include:
- Treatment & Disease Management is expected to dominate the market over the forecast period and this is attributed to the rise in disease burden and increasing demand for safe and effective treatments/therapies.
- Healthcare Providers Segment is expected to dominate the market during the forecast period and this is attributed to the increasing digitalization in the healthcare industry and increasing adoption digital healthcare solutions or services.
- Key players operating in the U.S. digital therapeutics market include 2Morrow Inc., ResMed, Pear Therapeutics, Omada Health Inc., Teladoc Health, Lark Technologies, Kaia Health, Fitbit, Cognoa Inc., and Akili Interactive Labs.
- Digital therapeutics are also vulnerable to third-party interference, signal errors, and transmission outages. This may result in the loss of critical patient data, hampering the growth of the U.S. digital therapeutics market.
